One case of central nervous system toxicity induced by loratinib tablets

doi:10.19803/j.1672-8629.20230330

Abstract

Abstract: Objective To explore the clinical characteristics and disposal of central nervous system toxicity caused by loratinib tablets. Methods One case of central nervous system toxicity caused by loratinib tablets in a stage IV lung adenocarcinoma patient with anaplastic lymphoma kinase (ALK) positivity was analyzed. By retrieving related literature, the clinical manifestations and appropriate treatments of such central nervous system toxicity were summarized. Results The main clinical manifestations were off-the-point answers, poor sleep, emotional excitement, irritability and inability to recognize others. This medication was discontinued immediately and symptomatic treatment with olanzapine was provided. The symptoms disappeared after three days, and the patient resumed the treatment with loratinib tablets after a week at a smaller dose. Conclusion Clinicians should be alert to the central nervous system toxicity associated with loratinib tablets, which can impact the quality of life of patients.

Key words: lorlatinib tablets, adverse drug reaction, central nervous system toxicity, anaplastic lymphoma kinase, lung adenocarcinoma

CLC Number:

JIANG Kun, TANFeilong, WANG Zhongjuan, TAN Hongcheng, YOU Li’na. One case of central nervous system toxicity induced by loratinib tablets[J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1432-1434.

References

[1] CHEN W, JIN D, SHI Y, et al.The underlying mechanisms of lorlatinib penetration across the blood-brain barrier and the distribution characteristics of lorlatinib in the brain[J]. Cancer Med, 2020, 9(12): 4350-4359.
[2] CHEN BC.New drugs for the treatment of non-small cell lung cancer-lorlatinib[J]. Herald of Medicine(医药导报), 2019, 38(7): 975-983.
[3] CHEN YC, HAN H, WEI JP, et al.Research progress in the efficacy and safety of alk inhibitors in the treatment of NSCLC brain metastasis[J]. Chinese Journal of Lung Cancer(中国肺癌杂志), 2023, 26(5): 400-406.
[4] Organization of the Guidelines Working Committee of the Chinese Clinical Oncology Society. Guidelines for the diagnosis and treatment of non-small cell lung cancer(中国临床肿瘤学会非小细胞肺癌诊疗指南)[M]. Beijing: People’s Health Press, 2022.
[5] BETTON M, GOUNANT V, SANNIER A, et al.Minimal change disease induced by lorlatinib[J]. J Thorac Oncol, 2018, 13(8): e154-e156.
[6] HAKAMATA J, NAKADA H, MURAMATSU H, et al. Lorlatinib-induced visual and auditory hallucinations: a case report[J]. Clin Case Rep, 2021, 9(8): 10.1002/ccr3.4040.
[7] ZHU VW, NAGASAKA M, KUBOTA T, et al.Symptomatic CNS radiation necrosis requiring neurosurgical resection during treatment with lorlatinib in ALK-rearranged NSCLC: a report of two cases[J]. Lung Cancer (Auckl), 2020, 11: 13-18.
[8] LAN ZY.A case of mental disorder caused by loratinib[J]. Journal of International Psychiatry(国际精神病学杂志), 2021, 48(3): 575-576.
[9] SISI M, FUSAROLI M, DE GIGLIO A, et al.Psychiatric adverse reactions to anaplastic lymphoma kinase inhibitors in non-small-cell lung cancer: analysis of spontaneous reports submitted to the FDA adverse event reporting system[J]. Target Oncol, 2022, 17(1): 43-51.
[10] DAGOGO-JACK I, ABBATTISTA A, MURPHY JF, et al.Factors associated with developing neurocognitive adverse events in patients receiving lorlatinib after progression on other targeted therapies[J]. J Thorac Oncol, 2023, 18(1): 67-78.
[11] ZHENG DN, ZHOU HF, REN CY, et al.ADR signal mining and analysis of adverse drug reaction of ceritinib[J]. China Pharmacy(中国药房), 2021, 32(2): 236-240.
[12] Pfizer Inc.OR BR ENA®(lorlatinib) tablets, for oral use. Initial U.S. Reference ID: 4756573[EB/OL]. [2023-03-26]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210868s004lbl.pdf.
[13] Novartis Pharma Stein AG.(ceritinib) tablets, for oral use[EB/OL].[2022-06-26]. https://zy.yaozh.com/instruct/sms20210831/89.pdf.
[14] NARANJO CA, BUSTO U, SELLERS EM, et al.A method for estimating the probability of adverse drug reactions[J]. Clin Pharmacol Ther, 1981, 30(2): 239-245.
[15] ZHOU Q, LU S, LI Y, et al.Chinese expert consensus on management of special adverse effects associated with lorlatinib[J]. Chinese Journal of Lung Cancer(中国肺癌杂志) , 2022, 25(8): 555-566.
[16] BAUER TM, FELIP E, SOLOMON BJ, et al.Clinical management of adverse events associated with lorlatinib[J]. Oncologist, 2019, 24(8): 1103-1110.
[17] U.S.Department of Health and Human Services. National Cancer Institute.Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0[EB/OL]. [2023-04-02]. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_50.